Skip to Content

Join the 'HIV Infection' group to help and get support from people like you.

HIV Infection News

Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS

Can HIV Drugs Boost Syphilis Risk?

Posted 9 hours ago by Drugs.com

MONDAY, Jan. 16, 2017 – Gay and bisexual men taking antiretroviral drugs to treat HIV infection may be at increased risk for syphilis, new research contends. Based on a review of available evidence, the investigators concluded that the drugs may boost susceptibility to the bacterium that causes syphilis, although the study did not prove cause-and-effect. The finding might explain why new and repeat cases of syphilis in gay and bisexual men have risen sharply compared to other sexually transmitted infections over the past decade, the researchers wrote. The study team was led by Dr. Michael Rekart, from the University of British Columbia's School of Population and Public Health in Vancouver. The findings were published in the Jan. 16 issue of the journal Sexually Transmitted Infections. The authors of an editorial that accompanied the study said the theory is "intriguing" and "warrants ... Read more

Related support groups: HIV Infection, Sexually Transmitted Diseases, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Syphilis, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Oseltamivir, Kaletra, Copegus, Entecavir

HIV May Double Odds of Heart Attack

Posted 22 Dec 2016 by Drugs.com

WEDNESDAY, Dec. 21, 2016 – As people with HIV are living longer, new concerns are cropping up, such as a risk for heart attack up to two times greater than for people without the AIDS-causing virus, a new study reports. Those increased odds are seen even in people whose virus has been suppressed to undetectable levels in the blood with antiretroviral drugs, the researchers said. There are several reasons for this higher risk, said lead researcher Dr. Matthew Feinstein, a cardiology fellow at Northwestern University Feinberg School of Medicine in Chicago. "A key factor appears to be chronic HIV-associated inflammation that persists even when there is no detectable virus in the blood," he said. Feinstein explained that the heart disease and stroke risk is higher "because the virus maintains a reservoir in the body's tissues, driving a chronic inflammatory and immune response that can ... Read more

Related support groups: Heart Attack, HIV Infection, Pre-Exposure Prophylaxis, Myocardial Infarction, Myocardial Infarction - Prophylaxis, Post MI Syndrome, Family History of Myocardial Infarction

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 1 Dec 2016 by Drugs.com

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked with resistance to older drugs called thymidine analogues. Among patients whose HIV had this mutation, 80 percent were also resistant to tenofovir, the main drug in most modern HIV treatment and prevention programs, the researchers reported. The findings were published in the Nov. 30 issue of The Lancet Infectious Diseases journal. "We were very surprised to see that so many people were resistant to both drugs, as we didn't think this was possible," study lead author Ravi Gupta, of University ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Sofosbuvir, Epclusa, Zepatier, Genvoya, Viread, Viekira Pak, Kaletra, Norvir

Use of Needle Exchange Programs Up Dramatically in 10 Years: CDC

Posted 30 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 30, 2016 – Although there was a significant increase in the use of syringe services programs (SSPs) – more commonly known as needle exchange programs – across the United States over the past decade, many injection drug users don't always use sterile needles, a federal government report says. Previously used needles put drug users at risk for infectious diseases such as HIV and hepatitis B and C, the report noted. Needle exchange programs provide sterile needles and syringes to injection drug users. These programs also refer drug users to prevention, care and treatment services. Researchers from the U.S. Centers for Disease Control and Prevention looked at data from injection drug users in 22 cities with high rates of HIV. In 2015, 54 percent of injection drug users said they used a needle exchange program in the past year. That was up significantly compared to the 36 ... Read more

Related support groups: Opiate Dependence, Hepatitis C, HIV Infection, Drug Dependence, Hepatitis B, Pre-Exposure Prophylaxis, Substance Abuse, Toxic Reactions Incl Drug and Substance Abuse, Hepatitis B Prevention, Exposure to Hepatitis B Virus, Hepatitis B Prophylaxis

U.S. Death Toll From Infectious Diseases Unchanged: Study

Posted 22 Nov 2016 by Drugs.com

TUESDAY, Nov. 22, 2016 – The war against infectious diseases – medicine versus microbes – has been holding steady, with the U.S. death rate from these diseases about the same now as it was in 1980, new research says. But some of the specific disease threats have changed over the years, the study authors noted. Researchers found that the national death rate from infections stood at almost 46 deaths per 100,000 people in 2014. That compared with 42 per 100,000 in 1980. There were some major shifts during that time, however. The overall death rate went as high as 63 per 100,000 in 1995, owing to the HIV/AIDS epidemic, according to the study. AIDS deaths declined from then on, with the introduction of the "drug cocktails" that have turned HIV into a manageable chronic disease. But while there was progress against HIV, deaths from pneumonia and flu complications held steady over the ... Read more

Related support groups: Bacterial Infection, Influenza, Pneumonia, HIV Infection, Clostridial Infection, Viral Infection, West Nile Virus, Adjunct to Antibiotic Therapy, Prevention of Clostridium Difficile Infection Recurrence

ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living With HIV

Posted 17 Nov 2016 by Drugs.com

Research Triangle Park, NC — On November 4, 2016, ViiV Healthcare received approval from the U.S. Food and Drug Administration (FDA) to market Selzentry for the treatment of only CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents, in pediatric patients 2 years of age or older who weigh at least 10 kilograms (kg).[1] Selzentry is a first-in-class CCR5 co-receptor antagonist designed to inhibit entry into the immune system’s CD4+ T-cells by CCR5-tropic HIV-1. Selzentry is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. In addition to the 150 milligram (mg) and 300 mg Selzentry tablets currently available, new 25 mg and 75 mg tablets and a 20 mg per milliliter (mL)oral solution will be available in January 2017. The dose of Selzentry in pediatric patients 2 years of age and older should be based on the patient’s body weight and the drug inter ... Read more

Related support groups: HIV Infection, Selzentry, Maraviroc

Can Time-Release Capsules Replace Daily Pills?

Posted 16 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 16, 2016 – A new type of drug capsule might one day replace the need to take medicines every day, but so far it has only been tested in pigs, researchers report. A capsule that contains a six-armed star containing drugs can remain in the stomach and release its medication over time. That means instead of taking daily medication, patients would only have to swallow one capsule weekly or monthly, the researchers said. "We have the potential for an ultra-long capsule for medications that folks are currently taking once or twice or three times a day – that can now be given once a week or once a month," said researcher Dr. Giovanni Traverso. He is an instructor in the division of gastroenterology at Brigham and Women's Hospital in Boston. "This can make life a lot easier, because patients are more likely to take a medication when it's dosed once a week versus once a day," ... Read more

Related support groups: Schizophrenia, Schizoaffective Disorder, HIV Infection, Renal Failure, Alzheimer's Disease, Pre-Exposure Prophylaxis, Chronic Kidney Disease, Hyperphosphatemia of Renal Failure

Drug Combo Shows Early Promise for Remission of HIV

Posted 10 Nov 2016 by Drugs.com

THURSDAY, Nov. 10, 2016 – Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission in people living with the virus, a new report says. The goal: to free patients from the need to take anti-HIV pills each day. Researchers combined an experimental vaccine with an immune-stimulating drug to create a one-two punch that caused a similar virus to become undetectable in three out of nine test monkeys, said senior author Dr. Dan Barouch. He's director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. "Both of these components already are in clinical trials being conducted separately," Barouch said. "We hope to evaluate the combination in humans, and we plan to do further animal studies as well. The experimental vaccine, called Ad26/MVA, aims to help the immune system target HIV. The ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Diagnosis and Investigation

Antibodies May Hold Key to HIV Suppression

Posted 10 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions of an anti-HIV antibody known as VRC01. The antibody was safe and repressed blood levels of HIV for a short time before the virus reappeared, the researchers said. HIV is the virus that can lead to AIDS. "We were not expecting that we were going to see a prolonged repression, because it was only a single antibody," said co-study author Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. The next phase is to infuse two or three antibodies intermittently, and see if antiretroviral drugs can be withdrawn permanently, he explained. After regular intravenous infusions of VRC01, participants in the U.S. National Institutes of ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Victrelis, Famciclovir, Famvir, Viread, Kaletra, Copegus, Tenofovir, Ribasphere, Valcyte, Entecavir, Norvir

Experimental Medicine Might Rescue People With Drug-Resistant HIV

Posted 28 Oct 2016 by Drugs.com

FRIDAY, Oct. 28, 2016 – Researchers report that a new medication might revolutionize the treatment of HIV patients who don't respond to existing drugs. The intravenous drug, known as ibalizumab, is given every two weeks. It's now in the final stage of research required before drug makers can seek U.S. government approval. "These are sick, vulnerable, desperate patients," said study author Dr. Jacob Lalezari, an assistant clinical professor of medicine at the University of California, San Francisco. "They're in a bind, and this is potentially a lifesaving therapy," said Lalezari, who is also medical director for Quest Clinical Research. The drug targets patients with multi-drug-resistant HIV, meaning they don't respond to many of the medications used to treat the AIDS-causing virus. It's estimated that 10,000 HIV patients in the United States are immune to several drugs, the researchers ... Read more

Related support groups: HIV Infection, AIDS Related Wasting, Diagnosis and Investigation

Nearly 3 Percent of U.S. Adults Have Weakened Immunity: Study

Posted 28 Oct 2016 by Drugs.com

FRIDAY, Oct. 28, 2016 – A new study reports that about 3 percent of people surveyed in the United States have a suppressed, or weakened, immune system. The statistics offer insight into the number of Americans who have immunity-suppressing conditions such as AIDS or take drugs that treat autoimmune disorders by weakening the immune system, the researchers said. The researchers believe these numbers are rising because of medical advances allowing immunosuppressed patients to live longer. Dr. Rafael Harpaz of the U.S. Centers for Disease Control and Prevention led the study. "Tracking immunosuppression over time is particularly important given the hundreds of clinical trials now under way to assess the use of immunosuppressive treatments for prevention or mitigation of common chronic diseases in highly prevalent risk groups," Harpaz and his colleagues wrote. The study authors explained ... Read more

Related support groups: HIV Infection, Autoimmune Disorders, Immunosuppression, Immunodeficiency

HIV May Hide in Tissues, Even After Treatment

Posted 27 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV in the blood and controls the disease. But the new findings suggest that HIV in the tissues may not cause AIDS but could contribute to the development of unrelated conditions, such as cancer and heart disease, according to the University of California, San Francisco (UCSF) researchers. "Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals," said study senior author Dr. Michael McGrath. "Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications," said McGrath. He is UCSF professor of laboratory medicine at the AIDS and Cancer ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Sovaldi, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Victrelis, Famciclovir, Sofosbuvir, Famvir, Viread, Kaletra, Copegus, Norvir, Tenofovir, Ribasphere

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Posted 26 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already debunked by the research: That there was a "Patient Zero" who somehow caused the epidemic of human immunodeficiency virus (HIV) in the United States. "In many ways, the historical evidence has been pointing to the fallacy of Patient Zero for decades," said Dr. Richard McKay, who studies the history behind the AIDS epidemic and was a co-author on the new study. "We now have additional [genetic] evidence that helps to consolidate this position," McKay said in a news release from the University of Cambridge in England. He is a professor in the university's departments of history and philosophy of science. The new genetic research was published Oct. 26 in the journal ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Viread, Kaletra, Entecavir, Norvir, Tenofovir, Telaprevir, Lamivudine, Boceprevir, Reyataz, Prezista, Diagnosis and Investigation, Nevirapine, Epivir, Zidovudine, Ritonavir, Lexiva

Monkey Study Hints at Drug-Free Suppression of HIV

Posted 13 Oct 2016 by Drugs.com

THURSDAY, Oct. 13, 2016 – Scientists may have found a way to suppress an HIV-like infection in monkeys, without the need for ongoing drug therapy. The researchers added antibody therapy to standard drug treatment given to macaque monkeys infected with simian immunodeficiency virus (SIV). After three months, the animals were taken off the drugs, but their viral levels remained low to undetectable – for close to two years. Experts stressed that the animal findings need to be viewed with caution, and that many questions remain. But, they were also hopeful this could lead to a therapy that frees at least some people from their HIV drug regimens. An initial safety study has already started at the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The drug "cocktails" used to treat HIV – known as combined antiretroviral therapy (ART) – have changed the face of the ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Kaletra, Ribasphere, Copegus, Valcyte, Norvir, Entecavir, Tenofovir, Ganciclovir

Doctors May Not Be Telling High-Risk Patients About HIV Prevention Drug

Posted 10 Oct 2016 by Drugs.com

MONDAY, Oct. 10, 2016 – Many gay and bisexual men don't know about a drug therapy that can protect them from HIV, a new study suggests. A once-a-day pill, Truvada, known as PrEP – short for pre-exposure prophylaxis medication – has been found to reduce HIV infection by 92 percent in people at high risk for the AIDS-causing virus, including men who have unprotected gay sex, the researchers said. The researchers studied 2014 data from 401 HIV-negative gay and bisexual men in Baltimore. Only 42 percent knew about PrEP. Those who had been tested for HIV in the previous year were more likely to be aware of it. But having recently seen a doctor or getting tested for another sexually transmitted disease did not increase the likelihood that gay or bisexual men knew about the preventive drug, the researchers from the Johns Hopkins Bloomberg School of Public Health found. The findings suggest ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Truvada

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Pre-Exposure Prophylaxis, Viral Infection

Related Drug Support Groups

Atripla, Truvada, Stribild, Triumeq, Complera, Genvoya, Viread, Kaletra, tenofovir, view more... Norvir, lamivudine, Reyataz, Privigen, nevirapine, Prezista, immune globulin intravenous, Combivir, ritonavir, Lexiva, zidovudine, abacavir, Tivicay, Epivir, Norvir Soft Gelatin, Sandoglobulin, Carimune, Trizivir, Intelence, Sustiva, Odefsey, lamivudine / zidovudine, indinavir, efavirenz, Descovy, didanosine, Epzicom, atazanavir, Fuzeon, Retrovir, Ziagen, Agenerase, Octagam, dolutegravir, Prezcobix, Edurant, raltegravir, nelfinavir, stavudine, darunavir, Telzir, amprenavir, Carimune NF, abacavir / dolutegravir / lamivudine, Isentress, Vitekta, Venoglobulin-S 5%, Evotaz, Dutrebis, Venoglobulin-S 10%, Tybost, Selzentry, Gammagard S / D, Gammar-P IV, Gamimune N 10%, Panglobulin, Panglobulin NF, Iveegam En, Gamimune N 5%, Gamimune, Viramune XR, Gammar IV, Gammaplex, Polygam S / D, Zerit XR, Crixivan, etravirine, zalcitabine, tipranavir, saquinavir, emtricitabine / lopinavir / ritonavir / tenofovir, emtricitabine / nelfinavir / tenofovir, cobicistat / elvitegravir / emtricitabine / tenofovir, emtricitabine / rilpivirine / tenofovir, rilpivirine, maraviroc, lopinavir / ritonavir, delavirdine, abacavir / lamivudine / zidovudine, abacavir / lamivudine, efavirenz / emtricitabine / tenofovir, emtricitabine, fosamprenavir, enfuvirtide, emtricitabine / tenofovir, elvitegravir, cobicistat, Viramune, Viracept, Epivir-HBV, Fortovase, Invirase, Hivid, Aptivus, Zerit, Emtriva, Videx EC, lamivudine / raltegravir, cobicistat / darunavir, atazanavir / cobicistat, cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, emtricitabine / rilpivirine / tenofovir alafenamide, Videx, Rescriptor, emtricitabine / tenofovir alafenamide, Flebogamma